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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Croatian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (7% systemic, 38% oligoarticular, 19% RF negative polyarthritis, 36% 
other categories) and 100 healthy children, were enrolled in the paediatric rheumatology centres of the Clinical Hospital 
Center Sestre Milosrdnice and Childen’s Hospital Srebrnjak in Zagreb. The JAMAR components discriminated well healthy 
subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. In conclusion, the 
Croatian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Croatian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Croatian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from September 
2013 to April 2016. Children were recruited after Ethics 
Committee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading, 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption (mean and standard deviation 
[SD] equivalence); the second Likert assumption or equal 
items-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
the 6 JIA core set variables, with the addition of the parent 
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assessment of disease activity and pain by the Spearman’s 
correlation coefficients (r) [17] and the discriminant valid-
ity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18]. Quantitative data were reported as medians with 1st 
and 3rd quartiles and categorical data as absolute frequen-
cies and percentages.
The complete Croatian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Croatian JAMAR was fully cross-culturally adapted 
from the standard English version with 2 forward and 2 
backward translations. The concordance rate between the 
original standard English version of the JAMAR and the 2 
back-translations was 91.7% (112/123 lines) for the parent 
version and 91.1% (110/120 lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 90–100%). The 
text of the parent and child JAMAR was unmodified after 
the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total of 
200 subjects), were enrolled at the paediatric rheumatology 
centres of the Clinical Hospital Center Sestre Milosrdnice 
and Children’s Hospital Srebrnjak in Zagreb.
In the 100 JIA subjects, the JIA categories were 7% with 
systemic arthritis, 38% with oligoarthritis, 19% with RF 
negative polyarthritis, 5% with RF positive polyarthritis, 
12% with enthesitis related arthritis and 19% with undif-
ferentiated arthritis (Table 1). Notably, none of the enrolled 
JIA patients is affected with psoriatic arthritis.
A total of 192/200 (96%) subjects had the parent version 
of the JAMAR completed by a parent (93 from parents of 
JIA patients and 99 from parents of healthy children). The 
JAMAR was completed by 151/192 (78.6%) mothers and 
41/192 (21.4%) fathers. The child version of the JAMAR 
was completed by 180/200 (90%) children age 5.5 years or 
older. Also patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 2.2% (1.1–5.9%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 8 and 9, whereas a reduced 
number of response choices was used for all the PF items 
except for items 1, 2, 3, 4 and 5.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (0–2%) for the PF and 2% (1–3%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 88.2% (82.8–93.5%) for the PF 
items, 60.2% (43–64.5%) for the HRQoL PhH items, and 
62.4% (48.4–69.9%) for the HRQoL PsH items. The median 
ceiling effect was 0.0% (0–1.1%) for the PF items, 3.2% 
(2.2–3.2%) for the HRQoL PhH items, and 1.1% (0–1.1%) 
for the HRQoL PsH items. The median floor effect was 43% 
for the pain VAS, 46.2% for the disease activity VAS and 
55.9% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 3.2% for the disease activity VAS 
and 1.1% for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the PF 
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items, with the exception of items 11, 12 and 15 and for 80% 
of the HRQoL items, with the exception of items 8 and 9.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for items 11 and 15) and 80% of items of 
the HRQoL (except for items 8 and 9).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.91 for PF-HW, 0.45 
for PF-US. Cronbach’s alpha was 0.88 for HRQoL PhH and 
0.74 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 93/192 Child N = 80/180
Missing values (1st–3rd quartiles) 2.2% (1.1–5.9%) 2.5% (1.3–5.0%)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 88.2% 90.0%
 HRQoL PhH 60.2% 67.5%
 HRQoL PsH 62.4% 65.0%
 Pain VAS 43.0% 40.0%
 Disease activity VAS 46.2% 46.2%
 Well-being VAS 55.9% 45.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 10.6% 1.3%
 HRQoL PsH 3.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 3.2% 0.0%
 Well-being VAS 1.1% 0.0%
Items with equivalent item-scale correlation 80% for PF, 80% for HRQoL 93% for PF, 93% for HRQoL
Items with items-scale correlation ≥ 0.4 87% for PF, 80% for HRQoL 60% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.87 0.76
 PF-HW 0.91 0.86
 PF-US 0.45 0.31
 HRQoL PhH 0.88 0.80
 HRQoL PsH 0.74 0.72
Items with item-scale correlation lower than the Cronbach alpha 87% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.95 0.88
 HRQoL PhH 0.96 1.00
 HRQoL-PsH 1.00 0.92
Spearman correlation with JIA core-set variables, median
 PF 0.3 0.4
 HRQoL PhH 0.3 0.4
 HRQoL PsH 0.2 0.3
 Pain VAS 0.3 0.3
 Disease activity VAS 0.2 0.2
 Well-being VAS 0.2 0.3
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of PF items 13 and 14.
Test–retest reliability
Reliability was assessed in 9 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 7 days (7–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.95). The ICC for the HRQoL PhH 
and for HRQoL PsH scores showed an almost perfect repro-
ducibility (ICC = 0.96 and ICC = 1.0, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 0.6 
(median = 0.3). The PF total score best correlation was 
observed with the global assessment of well-being (r = 0.6, 
p < 0.001). The correlation of the PF total score with the 
ESR and with the number of active joints was not signifi-
cant (p = 0.41 and p = 0.14, respectively). For the HRQoL, 
the median correlation of the PhH with the JIA core set of 
outcome variables ranged from 0.1 to 0.6 (median = 0.3), 
whereas for the PsH ranged from − 0.1 to 0.4 (median = 0.2). 
The PhH and the PsH showed the best correlation with the 
parent’s global assessment of well-being (r = 0.6 and r = 0.5, 
respectively, p < 0.001). The median correlations between 
the pain VAS, the well-being VAS, and the disease activ-
ity VAS and the physician-centred and laboratory measures 
were 0.3 (0.2–0.4), 0.2 (0.2–0.3), 0.2 (0.1–0.2), respectively.
Discussion
In this study, the Croatian version of the JAMAR was cross-
culturally adapted from the original standard English version 
with 2 forward and 2 backward translations. According to 
the results of the validation analysis, the Croatian parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls. The PhH, the PsH subscales and total 
score of the HRQoL scales proved to discriminate between 
the different JIA subtypes.
The disease-specific components of the questionnaire 
discriminated well between patients with JIA and healthy 
controls. Psychometric performances were good for all 
domains of the JAMAR with few exceptions: 2 PF items 
(“stretch arms” and “bite a sandwich or an apple” and “hav-
ing trouble getting alone with other children” and “having 
difficulty concentrating or paying attention”) showed a lower 
items internal consistency. However, the overall internal 
consistency was good for all the domains, with the excep-
tion of the PF-US Cronbach’s alpha.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were weak.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Croatian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
Acknowledgements We thank Marija Perica, MD, Josipa Piskovic, 
MD, and Ivana Rados, MD, for all the help with enrolment of partici-
pants. We thank all families who participated in the project, the team 
that prepared and reviewed the forward and backward translations, and 
all members of PRINTO in Croatia. We thank the staff of the PRINTO 
International Coordinating Centre in Genoa (Italy) and in particular 
Marco Garrone for the overall coordination of the translation process, 
Silvia Scala and Elisa Patrone for data collection and quality assur-
ance, Luca Villa, Giuseppe Silvestri and Mariangela Rinaldi for the 
database development and management and the remaining PRINTO 
team for data entry. The Principal Investigator of the study was Prof. 
Angelo Ravelli, MD. The scientific coordinator and study methodolo-
gist was Nicolino Ruperto, MD, MPH. The project coordinators were 
Alessandro Consolaro, MD, PhD, Francesca Bovis, BsA. We thank also 
Prof. Alberto Martini, PRINTO Chairman. Funding was provided by 
the Istituto G. Gaslini, Genoa (Italy). Permission for use of JAMAR 
and its translations must be obtained in writing from PRINTO, Genoa, 
Italy. All JAMAR-related inquiries should be directed to at printo@
gaslini.org. Permission for the use of CHAQ and CHQ derived-material 
is granted through the scientific cooperation of the copyright holder 
ICORE of Woodside CA and HealthActCHQ Inc. of Boston, Massa-
chusetts USA. All CHQ-related inquiries should be directed to licens-
ing@healthactchq.com. All CHAQ-related inquiries should be directed 
to gsingh@stanford.edu.
Funding This study was funded and coordinated by Istituto Giannina 
Gaslini, Genoa, Italy.
Compliance with ethical standards 
Conflict of interest Dr. Ruperto has received grants from BMS, Hoff-
man-La Roche, Janssen, Novartis, Pfizer, Sobi, during the conduct 
of the study and personal fees and speaker honorarium from Abbvie, 
Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, 
S121Rheumatology International (2018) 38 (Suppl 1):S115–S122 
1 3
Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD Serono, 
Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, 
Roche, Sanofi, Servier and Takeda. Dr. Consolaro, Dr. Bovis, Dr. Vid-
ovic, Dr. Harjacek, Dr. L. Lamot, Dr. M. Lamot, Dr. Paleka Bosak, Dr. 
Tambic Bukovac have nothing to disclose.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants included in the study as per the requirement of the local 
ethical committee.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi 
B, Magni-Manzoni S et al (2011) A new approach to clinical care 
of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimen-
sional Assessment Report. J Rheumatol 38(5):938–953
 2. Ruperto N, Martini A (2011) Networking in paediatrics: the exam-
ple of the Paediatric Rheumatology International Trials Organisa-
tion (PRINTO). Arch Dis Child 96(6):596–601
 3. Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, 
Garrone M et al (2012) Seeking insights into the EPidemiology, 
treatment and Outcome of Childhood Arthritis through a multi-
national collaborative effort: Introduction of the EPOCA study. 
Pediatr Rheumatol Online J 10(1):39
 4. Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone 
E et al (2018) Cross-cultural adaptation and psychometric evalu-
ation of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) in 54 languages across 52 countries: review of 
the general methodology. Rheumatol Int. https ://doi.org/10.1007/
s0029 6-018-3944-1 (in this issue)
 5. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Man-
ners P et al (1998) Revision of the proposed classification crite-
ria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 
25(10):1991–1994
 6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Gold-
enberg J et al (2004) International League of Associations for 
Rheumatology classification of juvenile idiopathic arthritis: sec-
ond revision, Edmonton, 2001. J Rheumatol 31(2):390–392
 7. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, 
Pistorio A, Viola S et al (2007) Development and validation of a 
new short and simple measure of physical function for juvenile 
idiopathic arthritis. Arthritis Rheum 57(6):913–920
 8. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M et al 
(1989) Development of a disability measurement tool for juvenile 
rheumatoid arthritis. The juvenile arthritis functional assessment 
scale. Arthritis Rheum 32:1390–1395
 9. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M 
et al (1991) Development of a disability measurement tool for 
juvenile rheumatoid arthritis. The juvenile arthritis functional 
assessment report for children and their parents. Arthritis Rheum 
34:873–880
 10. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measure-
ment of health status in children with juvenile rheumatoid arthri-
tis. Arthritis Rheum 37:1761–1769
 11. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lat-
tanzi B et al (2010) Evaluation of 21-numbered circle and 10-cen-
timeter horizontal line visual analog scales for physician and par-
ent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 
37(7):1534–1541
 12. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H 
(1997) The Juvenile Arthritis Quality of Life Questionnaire—
development of a new responsive index for juvenile rheuma-
toid arthritis and juvenile spondyloarthritides. J Rheumatol 
24(4):738–746
 13. Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS 
(2002) The PedsQL(TM) in pediatric rheumatology—reliabil-
ity, validity, and responsiveness of the Pediatric Quality of Life 
Inventory(TM) generic core scales and rheumatology module. 
Arthritis Rheum 46(3):714–725
 14. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 
1st edn. The Health Institute, New England Medical Center, 
Boston
 15. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio 
A, Solari N et al (2012) Parent and child acceptable symptom state 
in juvenile idiopathic arthritis. J Rheumatol 39(4):856–863
 16. Nunnally JC (1978) Psychometric theory, 2nd edn. McGraw-Hill, 
New York
 17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Mar-
tini A (1997) Preliminary definition of improvement in juvenile 
arthritis. Arthritis Rheum 40(7):1202–1209
 18. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) 
MAP-R for Windows: multitrait/multi-item analysis program—
revised user’s guide. Version 1.0 ed. Health Assessment Lab, 
Boston
Affiliations
Miroslav Harjacek1,2 · Lovro Lamot1,2 · Mirta Lamot1 · Mandica Vidovic1 · Edi Paleka Bosak1 · Lana Tambic Bukovac3 · 
Alessandro Consolaro4,5 · Francesca Bovis4 · Nicolino Ruperto4 · for the Paediatric Rheumatology International 
Trials Organisation (PRINTO)
 Miroslav Harjacek 
 miroslav.harjacek@zg.t-com.hr
 Mirta Lamot 
 mirta.lamot@gmail.com
 Mandica Vidovic 
 vidovicmand@yahoo.com
 Edi Paleka Bosak 
 epaleka@gmail.com
S122 Rheumatology International (2018) 38 (Suppl 1):S115–S122
1 3
 Lana Tambic Bukovac 
 lanabukovac@gmail.com
 Alessandro Consolaro 
 alessandroconsolaro@gaslini.org
 Francesca Bovis 
 francescabovis@gaslini.org
1 Division of Clinical Immunology and Rheumatology, 
Department of Pediatrics, Clinical Hospital Center Sestre 
Milosrdnice, Vinogradska cesta 29, 10000 Zagreb, Croatia
2 Department of Pediatrics, University of Zagreb School 
of Medicine, Zagreb, Croatia
3 Division of Rheumatology, Children’s Hospital Srebrnjak, 
Zagreb, Croatia
4 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology 
International Trials Organisation (PRINTO), Istituto 
Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
5 Dipartimento di Pediatria, Università di Genova, Genoa, Italy
